Michael Liebrenz

Summary

Affiliation: Psychiatric University Hospital
Country: Switzerland

Publications

  1. pmc High dose methylphenidate treatment in adult attention deficit hyperactivity disorder: a case report
    Michael Liebrenz
    Psychiatric University Hospital, Research Group on Substance Use Disorders, Selnaustrasse 9, 8001, Zurich, Switzerland
    J Med Case Rep 6:125. 2012
  2. ncbi Intravenous ketamine therapy in a patient with a treatment-resistant major depression
    Michael Liebrenz
    Psychiatric University Hospital, Research Group on Substance Use Disorders, Zurich, Switzerland
    Swiss Med Wkly 137:234-6. 2007
  3. ncbi Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression
    Michael Liebrenz
    Psychiatric University Hospital, Research Group on Substance Use Disorders, Zurich, Switzerland
    World J Biol Psychiatry 10:640-3. 2009
  4. doi Agonist substitution--a treatment alternative for high-dose benzodiazepine-dependent patients?
    Michael Liebrenz
    Research Group on Substance Use Disorders, Psychiatric University Hospital Zurich, Selnaustrasse 9, Zurich, Switzerland
    Addiction 105:1870-4. 2010
  5. pmc Do patients think cannabis causes schizophrenia? - A qualitative study on the causal beliefs of cannabis using patients with schizophrenia
    Anna Buadze
    Psychiatric University Hospital, Research Group on Substance Use Disorders, Selnaustrasse 9, 8001 Zurich, Switzerland
    Harm Reduct J 7:22. 2010
  6. ncbi High-Dose Benzodiazepine Users' Perceptions and Experiences of Anterograde Amnesia
    Michael Liebrenz
    Dr Liebrenz is Head of the Research Division, Department of Forensic Psychiatry, Institute of Forensic Medicine, University of Bern, Bern, Switzerland Mr Schneider is Resident Physician, Department of Surgery, Division of Visceral and Transplantation Surgery, University Hospital, Zurich, Switzerland Dr Buadze is Attending Physician, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland Ms Gehring is a Psychologist and Head of the Residential Rehabilitation Treatment Program, Ulmenhof, Sozialtherapie, Ottenbach, Switzerland Dr Dube is Attending Physician, County of Santa Barbara, Department of Behavioral Wellness, Santa Barbara, California Dr Caflisch is Attending Physician, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland Dr Liebrenz was financially supported by the Prof Dr Max Cloëtta Foundation, Zurich, Switzerland and the Uniscientia Foundation, Vaduz, Principality of Liechtenstein
    J Am Acad Psychiatry Law 44:328-37. 2016
  7. pmc High-Dose Benzodiazepine Dependence: A Qualitative Study of Patients' Perceptions on Initiation, Reasons for Use, and Obtainment
    Michael Liebrenz
    Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland
    PLoS ONE 10:e0142057. 2015
  8. ncbi Patient's perceptions of the cannabis-psychosis link--a systematic review
    Anna Buadze
    University of Zurich, Clinic of Affective Disorders and General Psychiatry, Lenggstrasse 31, 8032 Zurich, Switzerland
    Curr Pharm Des 18:5105-12. 2012

Collaborators

Detail Information

Publications8

  1. pmc High dose methylphenidate treatment in adult attention deficit hyperactivity disorder: a case report
    Michael Liebrenz
    Psychiatric University Hospital, Research Group on Substance Use Disorders, Selnaustrasse 9, 8001, Zurich, Switzerland
    J Med Case Rep 6:125. 2012
    ..Stimulant medication improves hyperactivity, inattention, and impulsivity in both pediatric and adult populations with Attention Deficit Hyperactivity Disorder (ADHD). However, data regarding the optimal dosage in adults is still limited...
  2. ncbi Intravenous ketamine therapy in a patient with a treatment-resistant major depression
    Michael Liebrenz
    Psychiatric University Hospital, Research Group on Substance Use Disorders, Zurich, Switzerland
    Swiss Med Wkly 137:234-6. 2007
    ..Recently, reports from North America have indicated that the intravenous infusion of ketamine hydrochloride (an N-methyl-d-aspartate receptor antagonist) results in a sudden and robust improvement of depression symptoms...
  3. ncbi Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression
    Michael Liebrenz
    Psychiatric University Hospital, Research Group on Substance Use Disorders, Zurich, Switzerland
    World J Biol Psychiatry 10:640-3. 2009
    ..This single-case trial was conducted to explore the duration of improvement and the effects of a second administration on the clinical outcome...
  4. doi Agonist substitution--a treatment alternative for high-dose benzodiazepine-dependent patients?
    Michael Liebrenz
    Research Group on Substance Use Disorders, Psychiatric University Hospital Zurich, Selnaustrasse 9, Zurich, Switzerland
    Addiction 105:1870-4. 2010
    ..Cognitive impairments, the most problematic side effects of substitution treatment with benzodiazepines, could possibly be minimized by using an optimal agonist...
  5. pmc Do patients think cannabis causes schizophrenia? - A qualitative study on the causal beliefs of cannabis using patients with schizophrenia
    Anna Buadze
    Psychiatric University Hospital, Research Group on Substance Use Disorders, Selnaustrasse 9, 8001 Zurich, Switzerland
    Harm Reduct J 7:22. 2010
    ....
  6. ncbi High-Dose Benzodiazepine Users' Perceptions and Experiences of Anterograde Amnesia
    Michael Liebrenz
    Dr Liebrenz is Head of the Research Division, Department of Forensic Psychiatry, Institute of Forensic Medicine, University of Bern, Bern, Switzerland Mr Schneider is Resident Physician, Department of Surgery, Division of Visceral and Transplantation Surgery, University Hospital, Zurich, Switzerland Dr Buadze is Attending Physician, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland Ms Gehring is a Psychologist and Head of the Residential Rehabilitation Treatment Program, Ulmenhof, Sozialtherapie, Ottenbach, Switzerland Dr Dube is Attending Physician, County of Santa Barbara, Department of Behavioral Wellness, Santa Barbara, California Dr Caflisch is Attending Physician, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland Dr Liebrenz was financially supported by the Prof Dr Max Cloëtta Foundation, Zurich, Switzerland and the Uniscientia Foundation, Vaduz, Principality of Liechtenstein
    J Am Acad Psychiatry Law 44:328-37. 2016
    ....
  7. pmc High-Dose Benzodiazepine Dependence: A Qualitative Study of Patients' Perceptions on Initiation, Reasons for Use, and Obtainment
    Michael Liebrenz
    Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland
    PLoS ONE 10:e0142057. 2015
    ..Although it is increasingly understood that treatment interventions should take subjective experiences and beliefs into account, the perceptions of this group of individuals remain under-investigated...
  8. ncbi Patient's perceptions of the cannabis-psychosis link--a systematic review
    Anna Buadze
    University of Zurich, Clinic of Affective Disorders and General Psychiatry, Lenggstrasse 31, 8032 Zurich, Switzerland
    Curr Pharm Des 18:5105-12. 2012
    ..Despite the heterogeneity of the included studies, findings are comparable and support the robustness of this review. Limitations and implications for clinicians and psychosis research are discussed...